Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

Inclusion Criteria: * Patients with multiple sclerosis for at least 6 months * Neurogenic detrusor overactivity without DSD * Symptoms of OAB * Patients capable of completing the bladder diary * Patients capable of independent toileting * Patients able to swallow the study medication in accordance to the protocol * Body Mass Index \>/= 18,8 kg/qm and \</= 35,0 kg/qm * documented, dated, written informed consent Exclusion Criteria: * Treatment with drugs known to affect mainly the urinary function 14 days prior to starting completion of the baseline diary for Visit 2 * Participation in a bladder-training program * Low compliance bladder (Compliance \<20 mL/cm H2O) * DSD, Detrusor hyporeflexia / areflexia and bradykinesia / tremor of the external urethral sphincter * Indwelling catheter or intermittent self-catheterization * Patience with post-void residual (PVR) urinary volume \> 200 mL at baseline * Urinary retention or clinically significant bladder outlet obstruction as detected by the investigator * Clinically predominant and bothersome stress urinary incontinence * Neurological diseases other than multiple sclerosis affecting urinary bladder function * Any urogenital surgery within 12 month prior to Visit 1 * 17 Additional Exclusion Criteria